Discover
CTNM
Contineum Therapeutics, Inc.
13.53
2 x 9.93
2 x 16.93
bid
ask
+
0.32
2.42%
2 @ 07:30 PM
13.53 +0.00 (0.00%)
| Ytd | 18.37% | |
| 1y | 9.11% |
13.14
day range
13.89
9.17
52 week range
17.57
| Open | 13.23 | Prev Close | 13.21 | Low | 13.14 | High | 13.89 | Mkt Cap | 509.01M |
| Vol | 2.14M | Avg Vol | 465.63K | EPS | -1.72 | P/E | N/A | Forward P/E | -7.68 |
| Beta | 0.75 | Short Ratio | 13.66 | Inst. Own | 72.39% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 10-29 | 50-d Avg | 15.24 | 200-d Avg | 13.64 | 1yr Est | 29.25 |
| Income Statement | |||
| Operating Expenses | 17.43M | ||
| Research and Development Expense | 12.70M | ||
| Selling, General and Administrative Expense | 4.73M | ||
| Operating Income | -17.43M | ||
| Net Income | -15.15M | ||
| Net Income Common Stock | -15.15M | ||
| Net Income Common Stock (USD) | -15.15M | ||
| Consolidated Income | -15.15M | ||
| Earnings per Basic Share | -0.40 | ||
| Earnings per Basic Share (USD) | -0.40 | ||
| Earnings per Diluted Share | -0.40 | ||
| Earning Before Interest & Taxes (EBIT) | -15.15M | ||
| Earning Before Interest & Taxes (USD) | -15.15M | ||
| Weighted Average Shares | 37.47M | ||
| Weighted Average Shares Diluted | 37.47M | ||
| Balance Sheet | |||
| Cash and Equivalents | 14.71M | ||
| Cash and Equivalents (USD) | 14.71M | ||
| Investments | 221.84M | ||
| Investments Current | 221.84M | ||
| Current Assets | 242.58M | ||
| Property, Plant & Equipment Net | 7.42M | ||
| Total Assets | 250.37M | ||
| Debt Current | 2.39M | ||
| Total Debt | 6.57M | ||
| Current Liabilities | 6.53M | ||
| Debt Non-Current | 4.18M | ||
| Total Liabilities | 10.71M | ||
| Accumulated Retained Earnings (Deficit) | -206.99M | ||
| Accumulated Other Comprehensive Income | -573.00K | ||
| Shareholders Equity | 239.66M | ||
| Shareholders Equity (USD) | 239.66M | ||
| Assets Non-Current | 7.79M | ||
| Total Debt (USD) | 6.57M | ||
| Liabilities Non-Current | 4.18M | ||
| Trade and Non-Trade Payables | 505.00K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 655.00K | ||
| Net Cash Flow from Financing | 1.20M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -5.45M | ||
| Capital Expenditure | -6.00K | ||
| Issuance (Purchase) of Equity Shares | 1.25M | ||
| Net Cash Flow from Investing | 4.85M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 4.86M | ||
| Net Cash Flow from Operations | -11.50M | ||
| Share Based Compensation | 3.84M | ||